
Researchers conducted a study on 1,137 children infected with Plasmodium falciparum malaria, focusing on the impact of Single Low-Dose Primaquine (SLDPQ) and Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency on hemoglobin (Hb) levels. The study included various treatment groups and G6PD statuses. Despite concerns about SLDPQ's effect on G6PD deficient patients, the research found that SLDPQ didn't significantly affect posttreatment Hb changes. Interestingly, G6PD deficient patients showed favorable posttreatment Hb changes and a higher chance of Hb recovery. These results support the use of SLDPQ without G6PD screening in African regions combating malaria. The study also identified factors influencing Hb dynamics, aiding in malaria treatment strategies.
Like
Save
Share